title: Comparison of graft-versus-host disease-free, relapse-free survival of transplantation using matched sibling donor, matched unrelated donor or unrelated cord blood after myeloablative conditioning for adult patients with hematological malignancies.
abstract: The novel composite endpoint of graft-versus-host disease/relapse-free survival (GRFS) was proposed to evaluate ideal healthy recovery without ongoing morbidity in patients undergoing allogeneic hematopoietic cell transplantation (HCT). We herein analyzed long-term GRFS based on the data of 256 patients with hematological malignancies who underwent allogeneic HCT after myeloablative conditioning. The probabilities of GRFS in the entire cohort were 60.1% at 1 year, and 48.6% at 5 years. Compared with unrelated cord blood, the probability of treatment failure as defined by GRFS at 5 years was similar with matched sibling donor (hazard ratio [HR]: 1.33; p = 0.28), but was significantly higher with matched unrelated donor (HR: 1.96; p = 0.01) in multivariate analysis. Unrelated cord blood achieved the highest proportion of patients who had not experienced any GRFS events at 5 years. These data suggest that long-term GRFS after HCT was similar in matched sibling donor recipients to unrelated cord blood recipients.
authors.affiliation: a Department of Hematology/Oncology , The Institute of Medical Science, The University of Tokyo , Tokyo , Japan.
authors.forename: Takaaki
authors.initials: T
authors.lastname: Konuma
authors.affiliation: a Department of Hematology/Oncology , The Institute of Medical Science, The University of Tokyo , Tokyo , Japan.
authors.forename: Seiko
authors.initials: S
authors.lastname: Kato
authors.affiliation: a Department of Hematology/Oncology , The Institute of Medical Science, The University of Tokyo , Tokyo , Japan.
authors.forename: Maki
authors.initials: M
authors.lastname: Oiwa-Monna
authors.affiliation: a Department of Hematology/Oncology , The Institute of Medical Science, The University of Tokyo , Tokyo , Japan.
authors.forename: Hiroto
authors.initials: H
authors.lastname: Ishii
authors.affiliation: a Department of Hematology/Oncology , The Institute of Medical Science, The University of Tokyo , Tokyo , Japan.
authors.forename: Arinobu
authors.initials: A
authors.lastname: Tojo
authors.affiliation: a Department of Hematology/Oncology , The Institute of Medical Science, The University of Tokyo , Tokyo , Japan.
authors.forename: Satoshi
authors.initials: S
authors.lastname: Takahashi
mesh_terms: D000293:Adolescent; D000328:Adult; D036101:Cord Blood Stem Cell Transplantation; D005260:Female; D006086:Graft vs Host Disease / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control; D019337:Hematologic Neoplasms / Q000175:diagnosis / Q000401:mortality* / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D035781:Siblings; D019172:Transplantation Conditioning / Q000009:adverse effects / Q000379:methods; D014184:Transplantation, Homologous; D017211:Treatment Failure; D016896:Treatment Outcome; D061349:Unrelated Donors; D055815:Young Adult
chemical_list: D007166:Immunosuppressive Agents
keywords: Allogeneic hematopoietic cell transplantation; graft-versus-host disease/relapse-free survival; matched sibling donor; matched unrelated donor; unrelated cord blood